Transcutaneous antigen delivery system

BMB Reports

Volumn 46, Issue 1, 2013, Pages 17-24

  Lee, Mi Young ^a   Shin, Meong Cheol ^b   Yang, Victor C ^b,c  

^a Soonchunhyang University   (South Korea)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Antigen delivery; Epidermis; Transcutaneous immunization; Vaccine

Indexed keywords

ANTIGEN; DRUG CARRIER; EXOTOXIN; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR;

CHEMISTRY; CPG ISLAND; HUMAN; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; SHORT SURVEY; SKIN; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANTIGENS; CPG ISLANDS; DRUG CARRIERS; EXOTOXINS; HUMANS; SKIN; TOLL-LIKE RECEPTORS; VACCINATION;

EID: 84874671248     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2013.46.1.001     Document Type: Short Survey

References (77)

1. Combadiere, B. and Liard, C. (2011) Transcutaneous and intradermal vaccination. Hum. Vaccine 7, 811-827.
2. Glenn, G. M., Scharton-Kersten, T., Vassell, R., Mallett, C. P., Hale, T. L. and Alving, C. R. (1998) Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161, 3211-3214.
3. Huang, Y., Park, Y. S., Moon, C., David, A. E., Chung, H. S. and Yang, V. C. (2010) Synthetic skin-permeable proteins enabling needleless immunization. Angew. Chem. Int. Ed. Engl. 49, 2724-2727.
4. Bal, S. M., Ding, Z., van Riet, E., Jiskoot, W. and Bouwstra, J. A. (2010) Advances in transcutaneous vaccine delivery: Do all ways lead to Rome? J. Control Release 148, 266-282.
5. Kirschner, N. and Brandner, J. M. (2012) Barriers and more: Functions of tight junction proteins in the skin. Ann. N. Y. Acad. Sci. 1257, 158-166.
6. Karande, P. and Mitragotri, S. (2010) Transcutaneous immunization: An overview of advantages, disease targets, vaccines, and delivery technologies. Annu. Rev. Chem. Biomol. Eng. 1, 175-201.
7. Clark, R. A. (2010) Skin-resident T cells: The ups and downs of on site immunity. J. Invest. Dermatol. 130, 362-370.
8. Glenn, G. M., Taylor, D. N., Li, X., Frankel, S., Montemarano, A. and Alving, C. R. (2000) Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat. Med. 6, 1403-1406.
9. Valladeau, J., Ravel, O., Dezutter-Dambuyant, C., Moore, K., Kleijmeer, M., Liu, Y., Duvert-Frances, V., Vincent, C., Schmitt, D., Davoust, J., Caux, C., Lebecque, S. and Saeland, S. (2000) Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12, 71-81.
10. Ochoa, M. T., Loncaric, A., Krutzik, S. R., Becker, T. C. and Modlin, R. L. (2008) "Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J. Invest. Dermatol. 128, 2225-2231.
11. Toebak, M. J., Gibbs, S., Bruynzeel, D. P., Scheper, R. J. and Rustemeyer, T. (2009) Dendritic cells: Biology of the skin. Contact Dermatitis 60, 2-20.
12. Romani, N., Clausen, B. E. and Stoitzner, P. (2010) Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol. Rev. 234, 120-141.
13. Zaba, L. C., Fuentes-Duculan, J., Steinman, R. M., Krueger, J. G. and Lowes, M. A. (2007) Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J. Clin. Invest. 117, 2517-2525.
14. Nestle, F. O., Zheng, X. G., Thompson, C. B., Turka, L. A. and Nickoloff, B. J. (1993) Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 151, 6535-6545.
15. Klechevsky, E., Liu, M., Morita, R., Banchereau, R., Thompson-Snipes, L., Palucka, A. K., Ueno, H. and Banchereau, J. (2009) Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol. 70, 281-288.
16. Bedoui, S., Whitney, P. G., Waithman, J., Eidsmo, L., Wakim, L., Caminschi, I., Allan, R. S., Wojtasiak, M., Shortman, K., Carbone, F. R., Brooks, A. G. and Heath, W. R. (2009) Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 10, 488-495.
17. Klechevsky, E., Morita, R., Liu, M., Cao, Y., Coquery, S., Thompson-Snipes, L., Briere, F., Chaussabel, D., Zurawski, G., Palucka, A. K., Reiter, Y., Banchereau, J. and Ueno, H. (2008) Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29, 497-510.
18. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Durand, I., Cella, M., Lanzavecchia, A. and Banchereau, J. (1997) CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 90, 1458-1470.
19. Dubois, B., Massacrier, C., Vanbervliet, B., Fayette, J., Brière, F., Banchereau, J. and Caux, C. (1998) Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J. Immunol. 161, 2223-2231.
20. Sixt, M., Kanazawa, N., Selg, M., Samson, T., Roos, G., Reinhardt, D. P., Pabst, R., Lutz, M. B. and Sorokin, L. (2005) The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22, 19-29.
21. Li, N., Peng, L. H., Chen, X., Nakagawa, S. and Gao, J. Q. (2011) Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 29, 6179-6190.
22. Bos, J. D. and Meinardi, M. M. (2000) The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9, 165-169.
23. Brown, M. B., Traynor, M. J., Martin, G. P. and Akomeah, F. K. (2008) Transdermal drug delivery systems: skin perturbation devices. Methods Mol. Biol. 437, 119-139.
24. Sieg, A. and Wascotte, V. (2009) Diagnostic and therapeutic applications of iontophoresis. J. Drug Target. 17, 690-700.
25. Batheja, P., Thakur, R. and Michniak, B. (2006) Transdermal iontophoresis. Expert Opin. Drug Deliv. 3, 127-138.
26. Charoo, N. A., Rahman, Z., Repka, M. A. and Murthy, S. N. (2010) Electroporation: an avenue for transdermal drug delivery. Curr. Drug Deliv. 7, 125-136.
27. Chen, X., Shah, D., Kositratna, G., Manstein, D., Anderson, R. R. and Wu, M. X. (2012) Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology. J. Control. Release 159, 43-51.
28. Vrdoljak, A., McGrath, M. G., Carey, J. B., Draper, S. J., Hill, A. V., O'Mahony, C., Crean, A. M. and Moore, A. C. (2012) Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J. Control. Release 159, 34-42.
29. Polat, B. E., Hart, D., Langer, R. and Blankschtein, D. (2011) Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. J. Control. Release 152, 330-348.
30. Peachman, K. K., Rao, M., Alving, C. R., Burge, R., Leppla, S. H., Rao, V. B. and Matyas, G. R. (2006) Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect. Immun. 74, 794-797.
31. Watabe, S., Xin, K. Q., Ihata, A., Liu, L. J., Honsho, A., Aoki, I., Hamajima, K., Wahren, B. and Okuda, K. (2001) Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 19, 4434-4444.
32. Wang, J., Hu, J. H., Li, F. Q., Liu, G. Z., Zhu, Q. G., Liu, J. Y., Ma, H. J., Peng, C. and Si, F. G. (2007) Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex. Exp. Dermatol. 16, 724-729.
33. Partidos, C. D., Beignon, A. S., Brown, F., Kramer, E., Briand, J. P. and Muller, S. (2002) Applying peptide antigens onto bare skin: Induction of humoral and cellular immune responses and potential for vaccination. J. Control. Release 85, 27-34.
34. Beignon, A. S., Briand, J. P., Muller, S. and Partidos, C. D. (2002) Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 105, 204-212.
35. Naohiro, S., Yoshiki, T., Takafumi N., Hideo, H., Fukumi, F. and Masahiro T. (2000) Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. U.S.A. 97, 371-376.
36. Hirobe, S., Matsuo, K., Quan, Y. S., Kamiyama, F., Morito, H., Asada, H., Takaya, Y., Mukai, Y., Okada, N. and Nakagawa, S. (2012) Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine 30, 1847-1854.
37. Joshi, N., Duhan, V., Lingwal, N., Bhaskar, S. and Upadhyay, P. (2012) Adjuvant properties of thermal component of hyperthermia enhanced transdermal immunization: effect on dendritic cells. PLoS One 7, e32067.
38. Brooks, N. A., Pouniotis, D. S., Tang, C. K., Apostolopoulos, V. and Pietersz, G. A. (2010) Cell-penetrating peptides: application in vaccine delivery. Biochim. Biophys. Acta 1805, 25-34.
39. Tarique, A. A., Kalsy, A., Arifuzzaman, M., Rollins, S. M., Charles, R. C., Leung, D. T., Harris, J. B., Larocque, R. C., Sheikh, A., Bhuiyan, M. S., Saksena, R., Clements, J. D., Calderwood, S. B., Qadri, F., Kovác, P. and Ryan, E. T. (2012) Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin. Vaccine Immunol. 19, 594-602.
40. Mawas, F., Peyre, M., Beignon, A. S., Frost, L., Del Giudice, G., Rappuoli, R., Muller, S., Sesardic, D. and Partidos, C. D. (2004) Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. J. Infect. Dis. 190, 1177-1182.
41. Slovin, S. F., Keding, S. J. and Ragupathi, G. (2005) Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 83, 418-428.
42. Ouerfelli, O., Warren, J. D., Wilson, R. M. and Danishefsky, S. J. (2005) Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities. Expert Rev. Vaccines 4, 677-685.
43. Skountzou, I., Quan, F. S., Jacob, J., Compans, R. W. and Kang, S. M. (2006) Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 24, 6110-6119.
44. El-Ghorr, A. A., Williams, R. M., Heap, C. and Norval, M. (2000) Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol. Med. Microbiol. 29, 255-261.
45. Zhang, J., Shi, Z., Kong, F. K., Jex, E., Huang, Z., Watt, J. M., Van Kampen, K. R. and Tang, D. C. (2006) Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect. Immun. 74, 3607-3617.
46. Mishra, D., Mishra, P. K., Dabadghao, S., Dubey, V., Nahar, M. and Jain, N. K. (2010) Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine 6, 110-118.
47. Benson, H. A. (2006) Transfersomes for transdermal drug delivery. Expert Opin. Drug Deliv. 3, 727-737.
48. Cui, Z. and Sloat, B. R. (2006) Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. Int. J. Pharm. 317, 187-191.
49. Vyas, S. P., Singh, R. P., Jain, S., Mishra, V., Mahor, S., Singh, P., Gupta, P. N., Rawat, A. and Dubey, P. (2005) Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int. J. Pharm. 296, 80-86.
50. Boyer, C. and Zasadzinski, J. A. (2007) Multiple lipid compartments slow vesicle contents release in lipases and serum. ACS Nano 1, 176-182.
51. Kim, Y. C., Ludovice, P. J. and Prausnitz, M. R. (2007) Transdermal delivery enhanced by magainin pore-forming peptide. J. Control. Release 122, 375-383.
52. Himes, R., Lee, S., McMenigall, K. and Russell-Jones, G. (2011) The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination. Vaccine 29, 5393-5398.
53. Tomoka, T-N., Erika, T., Megumi, K. and Koichi, T. (2012) Transcutaneous immunization system using a hydrotropic formulation induces a potent antigen-specific antibody response. PLoS One 7, e47980.
54. Gupta, R. K. and Siber, G. R. (1994) Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals 22, 53-63.
55. Beignon, A. S., Briand, J. P., Muller, S. and Partidos, C. D. (2001) Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology 102, 344-351.
56. Glenn, G. M., Rao, M., Matyas, G. R. and Alving, C. R. (1998) Skin immunization made possible by cholera toxin. Nature 391, 851.
57. Connell, T. D. (2007) Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev. Vaccines 6, 821-834.
58. Scharton-Kersten, T., Yu, Jm, Vassell, R., O'Hagan, D., Alving, C. R. and Glenn, G. M. (2000) Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68, 5306-5313.
59. Olvera-Gomez, I., Hamilton, S. E., Xiao, Z., Guimaraes, C. P., Ploegh, H. L., Hogquist, K. A., Wang, L. and Jameson, S. C. (2012) Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination. Proc. Natl. Acad. Sci. U.S.A. 109, 2072-2077.
60. Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J, and Narasimhan, B. (2009) Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 98, 1278-1316.
61. Riminton, D. S., Kandasamy, R., Dravec, D., Basten, A. and Baxter, A. G. (2004) Dermal enhancement: bacterial products on intact skin induce and augment organ-specific autoimmune disease. J. Immunol. 1, 302-309.
62. Rechtsteiner, G., Warger, T., Osterloh, P., Schild, H. and Radsak, M. P. (2005) Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174, 2476-2480.
63. Weldon, W. C., Zarnitsyn, V. G., Esser, E. S., Taherbhai, M. T., Koutsonanos, D. G., Vassilieva, E. V., Skountzou, I., Prausnitz, M. R. and Compans, R. W. (2012). Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One 7, e41501.
64. Scott, E. A., Stano, A., Gillard, M., Maio-Liu, A. C., Swartz, M. A. and Hubbell, J. A. (2012) Dendritic cell activation and T cell priming with adjuvant- and antigenloaded oxidation-sensitive polymersomes. Biomaterials 33, 6211-6219.
65. Chang, B. A., Cross, J. L., Najar, H. M. and Dutz, J. P. (2009) Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 27, 5791-5799.
66. Verthelyi, D. and Zeuner, R. A. (2003) Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24, 519-522.
67. Kim, D., Kwon, H. J. and Lee, Y. (2011) Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep. 44, 607-612.
68. Kim, D., Kwon, S., Ahn, C. S., Lee, Y., Choi, S. Y., Park, J., Kwon, H. Y. and Kwon, H. J. (2011) Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep. 44, 758-763.
69. Diwan, M., Tafaghodi, M. and Samuel, J. (2002) Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 85, 247-262.
70. Slütter, B., Bal, S. M., Ding, Z., Jiskoot, W. and Bouwstra, J. A. (2011) Adjuvant effect of cationic liposomes and CpG depends on administration route. J. Control. Release. 154, 123-130.
71. Ozaki, T., Yauchi, M., Xin, K. Q., Hirahara, F. and Okuda, K. (2005) Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant. Viral Immunol. 18, 373-380.
72. Belyakov, I. M., Hammond, S. A., Ahlers, J. D., Glenn, G. M. and Berzofsky, J. A. (2004) Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113, 998-1007.
73. Inoue, J. and Aramaki, Y. (2007) Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides. Vaccine 25, 1007-1013.
74. Hickey, D. K., Aldwell, F. E., Tan, Z. Y., Bao, S. and Beagley, K. W. (2009) Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection. Vaccine. 27, 6983-6990.
75. Hickey, D. K., Bao, S., Ikeda, L. T., Carey, A. J. and Beagley, K. W. (2005) Induction of anti-chlamydial mucosal immunity by transcutaneous immunization is enhanced by topical application of GM-CSF. Curr. Mol. Med. 5, 559-605.
76. Huang, C. M., Wang, C. C., Kawai, M., Barnes, S. and Elmets, C. A. (2006) Surfactant sodium lauryl sulfate enhances skin vaccination: molecular characterization via a novel technique using ultrafiltration capillaries and mass spectrometric proteomics. Mol. Cell. Proteomics 5, 523-532.
77. Karande, P., Arora, A., Pham, T. K., Stevens, D., Wojicki, A. and Mitragotri, S. (2009) Transcutaneous immunization using common chemicals. J. Control. Release 138, 134-140.